Compare NBIX & IREN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | IREN |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5B | 16.0B |
| IPO Year | 1996 | 2021 |
| Metric | NBIX | IREN |
|---|---|---|
| Price | $135.92 | $30.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 29 | 20 |
| Target Price | ★ $206.81 | $78.14 |
| AVG Volume (30 Days) | 1.3M | ★ 31.1M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 3.30 | N/A |
| Revenue | $161,626,000.00 | ★ $707,007,000.00 |
| Revenue This Year | $36.39 | $296.31 |
| Revenue Next Year | $16.93 | $160.88 |
| P/E Ratio | $40.95 | ★ N/A |
| Revenue Growth | ★ 977.51 | 41.11 |
| 52 Week Low | $122.14 | $28.93 |
| 52 Week High | $186.12 | $76.87 |
| Indicator | NBIX | IREN |
|---|---|---|
| Relative Strength Index (RSI) | 32.66 | 26.65 |
| Support Level | $125.18 | N/A |
| Resistance Level | $138.74 | $44.21 |
| Average True Range (ATR) | 3.60 | 2.13 |
| MACD | -0.05 | -1.27 |
| Stochastic Oscillator | 22.43 | 0.38 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
IREN owns data centers powered by renewable energy in Canada and the US for bitcoin mining and AI cloud infrastructure. The company is in the process of converting its existing bitcoin capacity for AI purposes and securing new power and land supply to expand its data center operation. IREN works closely with industry leaders in AI, such as Microsoft, to support their cloud infrastructure ambitions.